Latent Expands AI Platform to Unlock Access to a New Generation of Medicines

San Francisco, September 15, 2026. Latent, the enterprise pharmacy intelligence platform, today announced it is now live in 60 leading health systems across the U.S. that collectively serve about 70 million patients. New customers include Cleveland Clinic, AdventHealth, Cincinnati Children’s, Keck Medicine of USC, UNC Health, UnityPoint Health, and WVU Medicine. Latent also announced a suite of autonomous clinical agents built to bring life-changing treatments to patients faster. The agents are designed to accelerate access to high-demand drugs, including GLP-1s, and a new wave of highly complex specialty therapies across immunology, rheumatology, and cardiology.

“A treatment can exist, work, and still never reach the person who needs it because access is mired by complex coverage rules.”

“Advancements in medicine are outpacing the infrastructure built to get new therapies to patients,” said Sri Somasundaram, Co-Founder of Latent. “A treatment can exist, work, and still never reach the person who needs it because access is mired by complex coverage rules. We’re giving health systems the ability to extend the capacity of their pharmacy teams and get patients into the right treatment, without an unnecessary wait.”

Latent is on pace to process more than 5.8 million patient medication journeys in the next 12 months, spanning prior authorizations, compliance readiness reviews, and pharmacy work queues.

§ 02Preparing for a Surge in Drug Development

Powerful new therapies are entering the market at an unprecedented rate, offering the potential to transform the lives of millions of people. The specialty drug market was $226 billion in 2024 and is expected to grow to over $2.3 trillion by 2034, according to market research firm Global Market Insights. Specialty drugs now make up 50% of U.S. pharmacy drug spending. The increased use of AI to develop new therapies is expected to accelerate the arrival of increasingly complex medicines.

fig. 01 · specialty drug marketsource · Global Market Insights

2024$226B

2034E$2.3T

10× growth projected over the decade

“It allows us to focus more of our effort where it matters most, helping patients start treatment sooner.”

“The rapid growth of specialty and high-cost therapies is creating unprecedented and unrelenting pressure on medication access teams across the country,” said Robert Granko, Pharm.D., MBA, System Vice President, Pharmacy Business Operations for UNC Health. “At UNC Health, we have seen how intelligent automation can help our pharmacy teams manage growing demand, improve visibility across workflows, and accelerate access to therapy. Most importantly, it allows us to focus more of our effort where it matters most, helping patients start treatment sooner and supporting providers through an increasingly complex access landscape.”

Yet the infrastructure responsible for helping patients access those therapies has not kept pace with the rapid growth in specialty medications coming to market. Health systems nationwide are managing increasing administrative complexity associated with coverage requirements and patient eligibility reviews.

“The complex therapies and specialty medications these patients need require innovative solutions within our specialty pharmacies so we can help our patients access the right medications sooner.”

“At Keck Medicine of USC, we treat some of the most complicated and sickest patients in the nation,” explained Aman Mahajan, Associate Senior Vice President, USC Health Innovation. “The complex therapies and specialty medications these patients need require innovative solutions within our specialty pharmacies so we can help our patients access the right medications sooner.”

§ 03Autonomous Clinical Agents Bring High-Demand and Highly Complex Therapies to Patients, Faster

Novel therapeutics promise to transform patients’ lives, but as more drugs come to market, the administrative burden compounds and becomes unmanageable for pharmacy teams to keep pace. Latent’s autonomous clinical agents process unstructured data in the patient chart, claims data, payer policies, and drug labels, reasoning across that information and acting within each health system’s workflows. These autonomous agents operate in controlled health system workflows with oversight from clinical pharmacy teams. Latent’s clinical agents work across high-demand drugs, such as GLP-1s, and complex specialty therapeutics including immunology, rheumatology, and cardiology.

“The number of specialty medications coming to market today is growing faster than health systems can sustain.”

“At WVU Medicine, patient care and safety are our top priorities,” said Charles Barkey, Vice President, Clinical Applications at WVU Medicine. “The number of specialty medications coming to market today is growing faster than health systems can sustain. Technology that safely automates administrative work required to navigate increasingly complex therapies allows our pharmacists to focus their expertise on helping patients access the right treatment sooner.”

fig. 02 · GLP-1 Bridge responseJuly 2026

In just 10 days

Medicare launched the GLP-1 Bridge Program on July 1, 2026. 4 million Medicare members became eligible overnight.

In just 10 days, Latent securely deployed agents to autonomously evaluate eligibility for GLP-1s and gather the requisite information to submit prior authorizations.

Allowing hospitals to meet the rising demand and speed up patient access.

Partners are asking Latent to automate the most burdensome administrative tasks in controlled and governed workflows. For example, when Medicare launched the GLP-1 Bridge Program on July 1, 2026, 4 million Medicare members became eligible overnight. In just 10 days, Latent securely deployed agents to autonomously evaluate eligibility for GLP-1s and gather the requisite information to submit prior authorizations, allowing hospitals to meet the rising demand and speed up patient access.

Across its network, Latent and its health system partners are demonstrating that intelligence deployed across hospital pharmacy departments can improve patient access, experience, and outcomes.